IP Library › Granted Patent US 7,691,405
Granted Patent B2
US 7,691,405 · App. 12/027,952 · Granted Apr 6, 2010

Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,691,405
App. No.
12/027,952
Granted
Apr 6, 2010
Kind
B2
Abstract

The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver short interfering nucleic acid (siNA). The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).

Claims (10)

1. A lipid nanoparticle (LNP) composition comprising one or more short interfering nucleic acid (siNA) molecules, 3-Dimethylamino-2-(Cholest-5-en-3β-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy) propane (CLinDMA), Cholesterol, and polvethyleneglycol-diacylglycamide (PEG-DAG).

2. The LNP composition of claim 1 , further comprising Linoleyl alcohol.

3. The LNP composition of claim 1 , wherein said polyethyleneglycol diacylglycerol (PEG-DAG) is 1-[8′-(1,2-Dimyristoyl-3-propanoxy) -carboxamido-3′,6′-dioxaoctanyl] carbamoyl-ω-methyl-poly(ethylene glycol) (PEG-DMG).

4. The LNP composition of claim 1 , wherein said siNA molecule comprises a sense strand and an antisense strand, each comprising one or more pyrimidine nucleotides and one or more purine nucleotides.

5. The LNP composition of claim 4 , wherein one or more purine nucleotides present in said sense strand are 2′-deoxy purine nucleotides.

6. The LNP composition of claim 4 , wherein one or more purine nucleotides present in said antisense strand are 2′-O-methyl purine nucleotides.

7. The LNP composition of claim 4 , wherein one or more pyrimidine nucleotides present in said sense strand are 2′-deoxy-2′-fluoro nucleotides.

8. The LNP composition of claim 4 , wherein one or more pyrimidine nucleotides present in said antisense strand are 2′-deoxy-2′-fluoro nucleotides.

9. A composition comprising the LNP composition of claim 1 in a pharmaceutically acceptable carrier or diluent.

10. The LNP composition of claim 4 , wherein said siNA molecule comprises one or more ribonucleotides.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →